|
News For RHHBY;ABBV From The Last 14 Days Check below for free stories on RHHBY;ABBV the last two weeks. |
|
|
| May 22, 2013 |
| 10:33 EDT |  | RHHBY | Bristol-Myers jumps after Citi ups rating on cancer potential
 Subscribe for More Information |
|
| 10:00 EDT |  | RHHBY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:02 EDT | | RHHBY | Roche upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT |  | RHHBY | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| May 20, 2013 |
| 17:26 EDT | | RHHBY | Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement'
Subscribe for More Information |
|
| 17:20 EDT | | RHHBY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 10:51 EDT | | ABBV | AbbVie initiates Phase 3 clinical study for atrasentan
Subscribe for More Information |
|
| 07:42 EDT |  | ABBV | Cohasset Associates to host a conference
National Conference on Managing Electronic Records is being held in Chicago on May 20-22. |
|
| May 17, 2013 |
| 05:15 EDT | | ABBV | Galapagos, AbbVie extend GLPG0634 collaboration
Galapagos and AbbVie announced an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 of 2015, AbbVie will pay Galapagos $50M. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities. Galapagos will start an 20-week, Phase 2A/B study with GLPG0634 in 180 patients suffering from Crohn's disease by early 2014. |
|
| May 16, 2013 |
| 08:55 EDT | | ABBV | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
| |
| May 15, 2013 |
| 17:26 EDT | | ABBV | Third Point gives quarterly update on stakes
NEW STAKES: Virgin Media (VMED), Tiffany (TIF), B/E Aerospace (BEAV), Anadarko (APC), and Thermo Fisher (TMO). INCREASED STAKES: International Paper (IP), Abbvie (ABBV), TransDigm (TDG), Constellation Brands (STZ), and Dollar General (DG). DECREASED STAKES: Delphi (DLPH), Murphy Oil (MUR), AIG (AIG), LyondellBasell (LYB), and Liberty Global (LBTYA). LIQUIDATED STAKES: Tesoro (TSO), Morgan Stanley (MS), Symantec (SYMC), Herbalife (HLF), and Illumina (ILMN). |
|
| 15:59 EDT | | RHHBY | Roche exploring sale of blood glucose meters unit, Reuters says
Subscribe for More Information |
|
| 12:13 EDT | | RHHBY | Roche management to meet with Jefferies
Meeting to be held in London on May 17 hosted by Jefferies. |
|
| 11:38 EDT | | RHHBY | Roche says FDA approves Tarceva tablets for specific lung cancer situation
Subscribe for More Information |
|
| 10:13 EDT |  | ABBV | On The Fly: Analyst Initiation Summary
Subscribe for More Information |
|
| 07:59 EDT | | ABBV | AbbVie initiated with an Outperform at Cowen
Subscribe for More Information |
|
| May 14, 2013 |
| 16:55 EDT | | RHHBY | FDA approves Roche's cobas EGFR mutation test with Tarceva
Subscribe for More Information |
|
| 10:20 EDT |  | ABBV | AbbVie volatility at 22 into ASCO
Subscribe for More Information |
|
| 09:27 EDT | | ABBV | AbbVie and Alvine Pharmaceutical enter into collaboration
Subscribe for More Information |
|
| 07:24 EDT | | ABBV | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. |
| |
|
|
|
|
